Investigation of pleiotropic effect of DPP-4 inhibitor, sitagliptin for type 2 diabetic patients with old myocardial infarctio
- Conditions
- type 2 diabetic patients with old myocardial infarction
- Registration Number
- JPRN-UMIN000012562
- Lead Sponsor
- Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, MUSIC FAIR Project Office
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
1. Patients with type 1 diabetes 2. Patients who had a history of severe ketosis, diabetic coma or precoma within 6 mnths 3. Patients who had a history of acute myocardial infarction and unstable angina 4. Patients who had a history of coronary bypass surgery, prosthetic replacement and pacemaker implantation 5. Patients with severe heart failure (NYHA IV) 6. Patients with transient and persistent atrial fibrillation 7. Patients before or after operation, and those with severe infections or serious injury 8. Pregnant, possible pregnant, or lactating women 9. Patinets with severe kidney dysfunction (eGFR: <30mL/min or patients under dialysis) 10. Patients with severe liver dysfunction 11. Patients that cardiac MRI is contraindicated 12. Patients receiving insulin or GLP-1 receptor analogues injection 13. Patients receiving glinide and alpha glucosidase inhibitor 14. Patients with a history of hypersensitivity to the study drug 15. Patients receiving DPP-4 inhibitor 16. Patients who are considered not eligible for the study by the attending doctor due to other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in myocardial perfusion reserve by cardiac MRI after 6 months of treatment
- Secondary Outcome Measures
Name Time Method 1. Changes in myocardial fibrosis by cardiac MRI after 6 months of treatment 2. Changes in left ventricular end-diastolic volume, end-systolic volume, and ventricular mass by cardiac MRI after 6 months of treatment 3. Changes in RH-PAT index by reactive hyperemia peripheral arterial tonometry after 6 months of treatment 4. Changes in home blood pressure after 6 months of treatment 5. adverse events